# Reassessing the link between adiposity and head and neck cancer: a Mendelian randomization study

Fernanda Morales-Berstein<sup>1,2</sup>, Jasmine Khouja<sup>1,2</sup>, Mark Gormley<sup>1-3</sup>, Elmira Ebrahimi<sup>4</sup>, Shama Virani<sup>4</sup>, James McKay<sup>4</sup>, Paul Brennan<sup>4</sup>, Tom G Richardson<sup>1,2</sup>, Caroline L Relton<sup>1,2,5</sup>, George Davey Smith<sup>1,2</sup>, M Carolina Borges<sup>1,2</sup>, Tom Dudding<sup>1-3</sup>, Rebecca C Richmond<sup>1,2</sup>

<sup>1</sup>MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom. <sup>2</sup>Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

<sup>3</sup>University of Bristol Dental School, 1 Trinity Walk, Avon Street, Bristol, United Kingdom. <sup>4</sup>Genomic Epidemiology Branch, International Agency for Research on Cancer, World Health Organization, Lyon, France.

<sup>5</sup>London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom.

For correspondence: dy20206@bristol.ac.uk

**Keywords**: Head and neck cancer, adiposity, body mass index, waist-to-hip ratio, waist circumference, Mendelian randomization.

## 1 Abstract

- 2 Background: Adiposity has been associated with an increased risk of head and neck cancer
- 3 (HNC). Although body mass index (BMI) has been inversely associated with HNC risk among
- 4 smokers, this is likely due to confounding. Previous Mendelian randomization (MR) studies
- 5 could not fully discount causality between adiposity and HNC due to limited statistical power.

6 Hence, we aimed to revisit this using the largest genome-wide association study (GWAS) of

7 HNC available, which has more granular data on HNC subsites.

8

9	Methods: We assessed the genetically predicted effects of BMI (N=806,834), waist-to-hip
10	ratio (WHR; N=697,734) and waist circumference (N=232,101) on the risk of HNC (N=12,264
11	cases and 19,259 controls) and its subsites (oral, laryngeal, hypopharyngeal and
12	oropharyngeal cancers) using a two-sample MR framework. We used the inverse variance
13	weighted (IVW) MR approach and multiple sensitivity analyses including the weighted
14	median, weighted mode, MR-Egger, MR-PRESSO, and CAUSE approaches. We also used
15	multivariable MR (MVMR) to explore the direct effects of the adiposity measures on HNC,
16	while accounting for smoking behaviour, a well-known HNC risk factor.
17	
18	Results: In univariable MR, higher genetically predicted BMI increased the risk of overall
19	HNC (IVW OR=1.17 per 1 standard deviation [1-SD] higher BMI, 95% CI 1.02–1.34, p=0.03),
20	with no heterogeneity across subsites (Q p=0.78). However, the effect was not consistent in
21	sensitivity analyses. The IVW effect was attenuated when smoking was included in the
22	MVMR model (OR accounting for comprehensive smoking index=0.96 per 1-SD higher BMI,
23	95% CI 0.80–1.15, p=0.64) and CAUSE indicated the IVW results could be biased by
24	correlated pleiotropy. Furthermore, we did not find a link between genetically predicted
25	WHR (IVW OR=1.05 per 1-SD higher WHR, 95% CI 0.89–1.24, p=0.53) or waist circumference
26	and HNC risk (IVW OR=0.83 per 1-SD higher waist circumference, 95% Cl 0.56–1.23, p=0.35).
27	
28	<b>Conclusions</b> : Our findings suggest that adiposity does not play a role in HNC risk.

29

It is made available under a CC-BY 4.0 International license .

# 30 Introduction

31	Head and neck cancer (HNC) is among the ten most common cancers in Europe, with an age
32	standardised incidence rate of 10.3 per 100,000 person-years[1]. Around 90% of HNCs are
33	classed as squamous cell carcinomas of the oral cavity, pharynx or larynx[2]. Tobacco
34	smoking and alcohol consumption are well-established HNC risk factors[3-9]. High-risk
35	human papillomavirus (HPV) infection has also been causally linked to the risk of HNC,
36	especially oropharyngeal cancer[10-12]. In contrast, the role of adiposity in the development
37	of HNC is less well understood.
38	
39	The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR)
40	Continuous Update Project (CUP) Expert Report published in 2018 determined higher body
41	fatness (i.e., body mass index [BMI], waist-to-hip ratio [WHR] and waist circumference) likely
42	increases the risk of HNC[13]. The CUP panel reached this conclusion even though a higher
43	BMI has been associated with a decreased risk of HNC[13], since they noted the inverse
44	association appears to be limited to current smokers. They concluded the association
45	between BMI and HNC risk may be biased among individuals who smoke (because smoking
46	is a HNC risk factor associated with lower weight). It is thought that nicotine consumption
47	could lead to appetite suppression and increased energy expenditure, which could in turn,
48	lead to weight loss (and spurious inverse associations between BMI and HNC risk[14])
49	among smokers[15]. Among never smokers, BMI has been positively associated with HNC
50	risk, in line with the evidence observed for measures of central adiposity (i.e., WHR and
51	waist circumference)[14, 16].

52

53	However, the relationship between adiposity and smoking is complex, with evidence from
54	Mendelian randomization (MR) studies suggesting higher adiposity increases the risk of
55	smoking[17, 18] while simultaneously suggesting smoking may lead to lower adiposity[17,
56	19-22]. Additionally, excess adiposity, socioeconomic deprivation and (both active and
57	passive) smoking are often strongly correlated[23-26]. Thus, the positive associations
58	between adiposity (i.e., BMI among non-smokers, WHR and waist circumference) and HNC
59	risk may not be as unbiased as they appear.
60	
61	It is important to acknowledge that previous MR studies on adiposity (i.e., BMI, WHR, waist
62	circumference) and HNC risk were relatively small (maximum N=6,034 cases) and could not
63	fully discount causality due to limited statistical power[27-29]. Therefore, the aim of this MR
64	study was to revisit the link between adiposity and HNC risk using data from a HNC genome-
65	wide association study (GWAS) that includes over two times the number of cases than the
66	Genetic Associations and Mechanisms in Oncology (GAME-ON) GWAS[30] used by Gormley
67	et al.[28] (the largest to date; N=12,619, including 6,034 cases and 6,585 controls) and has

68 more granular data on HNC subsites (i.e., oral cavity, hypopharynx, oropharynx and larynx).

69 We also aimed to use multivariable MR (MVMR) to explore the direct effects of the adiposity

70 measures on HNC, while accounting for smoking behaviour.

It is made available under a CC-BY 4.0 International license .

## 72 Methods

#### 73 Study design

- 74 We used a two-sample MR framework to assess the genetically predicted effects of BMI,
- 75 WHR and waist circumference on the risk of HNC and its subsites (oral, laryngeal,
- 76 hypopharyngeal and oropharyngeal cancers) among individuals of European ancestry.
- 77 Genetic variants associated with these adiposity traits were used as instrumental variables
- to estimate causal effects under the three core MR assumptions[31]: 1) the genetic variants
- are strongly associated with the adiposity trait of interest (relevance assumption); 2) the
- 80 distribution of the genetic variants in the population is not influenced by factors that also
- 81 influence HNC risk, such as population stratification, assortative mating and dynastic effects
- 82 (independence assumption); and 3) the genetic variants can only influence HNC risk via their
- 83 effect on the adiposity trait of interest (exclusion restriction assumption). This work was
- conducted and reported according to the STROBE-MR guidelines[32] (Additional File 1:
- 85 Appendix).

86

#### 87 Head and neck cancer GWAS

GWAS summary statistics for HNC were obtained from a European HEADSpAcE consortium
GWAS that excluded UK Biobank participants (N=31,523, including 12,264 cases and 19,259
controls) to avoid overlapping samples across the exposure and outcome datasets. It
includes the European GAME-ON data used by Gormley et al.[30] and has more granular
data on HNC subsites (i.e., oral cavity [N=21,269, including 3,091 cases and 18,178 controls],
hypopharynx [N=18,652, including 474 cases and 18,178 controls], HPV positive oropharynx
[N=20,146, including 1,980 cases and 18,166 controls], HPV negative oropharynx [N=19,114,

It is made available under a CC-BY 4.0 International license .

95	including 948 cases and 18,166 controls] and larynx [N=20,668, including 2,490 cases and
96	18,178 controls])[33].
97	

HNC was defined based on the 10<sup>th</sup> revision of the International Classification of Diseases

99	(ICD-10)[34]. It included cancers of the oral cavity (C00.3, C00.4, C00.5, C00.6, C00.8, C00.9,
100	C02.0–C02.9 [except C02.4], C03.0–C03.9, C04.0–C04.9, C05.0–C06.9 [except C05.1, C05.2]),
101	the oropharynx (C01-C01.9, C02.4, C05.1, C05.2, and C09.0–C10.9), the hypopharynx (C12.0-
102	C13.0), the larynx (C32), and overlapping or not otherwise specified sites (C14, C05.8, C02.8,
103	C76.0)[33].
104	
105	Further detail on the HEADSpAcE GWAS has been published elsewhere[33]. In brief,
106	genotype data were obtained using nine different genotyping arrays. They were
107	subsequently converted to genome build 38 for consistency across datasets. Quality control
108	(QC) procedures were conducted by genotyping array rather than by study. Samples were
109	excluded for the following reasons: sex mismatch (heterozygosity <0.8 for males and >0.2 for
110	females), autosomal heterozygosity (>3 standard deviation [SD] units from the mean),
111	missingness (>0.03), and cryptic relatedness (identity-by-decent >0.185). Single nucleotide
112	polymorphisms (SNPs) were removed due to genotype missingness (>0.01), deviations from
113	Hardy-Weinberg equilibrium ( $ ho$ <1e-05) and low minor allele count (<20). Imputation was
114	performed using the TOPMed Imputation Server. Only SNPs with an imputation score $r^2 > 0.3$
115	and a minor allele frequency (MAF) >0.005 were included in the GWAS. The analyses were
116	conducted in PLINK using logistic regressions adjusted for sex, the top principal components
117	and imputation batch (six in total, which account for both genotyping array and study

118 differences).

98

It is made available under a CC-BY 4.0 International license .

1		1		q
-	-	-	-	-

#### 120 Genetic instruments for adiposity

- 121 GWAS summary statistics for waist circumference (N=232,101) in SD units were obtained
- 122 from the Genetic Investigation of Anthropometric Traits (GIANT) meta-analysis by Shungin et
- al.[35] available via the IEU OpenGWAS platform (id: ieu-a-61). GWAS summary statistics for
- BMI (N=806,834) and WHR (N=697,734) in SD units were obtained from the latest GIANT
- 125 consortium's GWAS meta-analysis by Pulit et al.[36] available at
- 126 <u>https://zenodo.org/records/1251813</u>. The meta-analysis is the biggest to date, as it
- 127 combines the meta-analysis by Shungin et al. [35] with UK Biobank data. The UK Biobank
- 128 GWAS[36] was conducted using imputed data and the BOLT-LMM software[37]. The linear
- 129 mixed models (LMMs) were solely adjusted for genotyping array. GIANT and UK Biobank
- 130 data were meta-analysed[36] using an inverse-weighted fixed-effect meta-analysis in
- 131 METAL[38].
- 132
- 133 We extracted GWAS-significant SNPs for waist circumference using the standard threshold
- 134 (p<5e-08). For BMI and WHR, we extracted them according to the stringent threshold
- recommended by Pulit et al. [36] to account for denser imputation data (p<5e-09). We then
- 136 performed LD-clumping to select independent lead SNPs for each exposure ( $r^2$ =0.001,
- 137 10,000 kb). In total, 458 and 283 and 41 SNPs remained for BMI, WHR and waist
- 138 circumference, respectively.

139

#### 140 Data harmonisation

141 We extracted HNC GWAS summary statistics that corresponded to the list of SNPs selected

142 as instruments for the exposures. Proxy SNPs ( $r^2$ >0.8) were used when the instrumental

It is made available under a CC-BY 4.0 International I	license.
--	----------

143	SNPs were not available in the outcome datasets. Proxies were identified using the
144	<pre>"extract_outcome_data" function of the "TwoSampleMR" R package and the 1000 Genomes</pre>
145	Project European reference panel. We harmonised the exposure and outcome datasets
146	using the "harmonise_data" function of the "TwoSampleMR" R package[39]. Positive strands
147	were inferred using allele frequencies and ambiguous palindromic SNPs with MAFs $\geq$ 0.3
148	were removed. The harmonised data used in the analyses are available in <b>Supplementary</b>
149	Tables 1 to 6 (Additional File 2).
150	
151	We calculated mean F-statistics and total $R^2$ values to assess the strength of our genetic
152	instruments after data harmonisation[40, 41].
153	
154	Statistical analysis
155	Main analyses
156	The multiplicative random effects inverse-variance weighted (IVW) MR approach[42] (the
157	default IVW method of the "TwoSampleMR" package[39]) was used to investigate the
158	genetically predicted effects of BMI, WHR and waist circumference on HNC risk. We did not
159	correct our results for multiple testing, as all our exposures are strongly correlated [35, 36].
160	
161	Sensitivity analyses
162	Because the IVW method assumes all genetic variants are valid instruments[42], which is
163	unlikely the case, three pleiotropy-robust two-sample MR methods (i.e., MR-Egger[43],
164	weighted median[44] and weighted mode[45]) were used in sensitivity analyses. We also
165	performed tests for SNP heterogeneity (i.e., Q statistic test)[46] and directional horizontal
166	pleiotropy (i.e., MR-Egger intercept test)[43]. When directional horizontal pleiotropy was

identified, we used the intercept value to evaluate the extent of the bias. The MRPRESSO[47] method was used to identify outliers (outlier test p<0.05) and calculate outlier-</li>
corrected causal estimates when there was evidence of SNP heterogeneity. The MR-PRESSO
distortion test was used to evaluate differences between the outlier-corrected and IVW
estimates.
In addition, we ran MVMR[48] analyses to evaluate the direct effects of adiposity measures

174 with evidence of a total effect in our main analyses. The aim of the MVMR analyses was to 175 separate the effect of adiposity from smoking behaviour (a well-known HNC risk factor 176 which has a complex relationship with adiposity) in the development of HNC. We obtained genetic instruments for smoking behaviour from two different sources: a smoking initiation 177 178 GWAS (N=805,431 excluding 23andme) derived by the GWAS and Sequencing Consortium of 179 Alcohol and Nicotine use (GSCAN)[49] and a comprehensive smoking index (CSI; a measure of lifetime smoking that captures smoking heaviness, duration and cessation) GWAS 180 181 (N=462,690) conducted by Wootton et al. [50]. Each was separately investigated in a MVMR 182 framework. For each smoking trait, we selected SNPs that passed the GWAS-significance and independence thresholds (p<5e-08,  $r^2=0.001$ , 10,000 kb) and combined them with the list of 183 184 SNPs identified as instruments for the relevant exposure. We then performed LD-clumping 185 across the combined list of SNPs, to then use these independent SNPs in MVMR analyses. 186 The exposure and outcome datasets were harmonised to the same effect allele using the 187 "harmonise data" function of the "TwoSampleMR" R package[39]. We formatted the data 188 using the "format mvmr" function of the "MVMR" R package, calculated the conditional F-189 statistics for the MVMR instruments using the "strength mvmr" function and ran the MVMR 190 analyses using the "ivw mvmr" function.

It is made available under a CC-BY 4.0 International license .

191

192	Since we used large GWAS datasets for the selection of our genetic instruments, our
193	analyses are at an increased likelihood of being biased due to correlated horizontal
194	pleiotropy (sometimes referred to as heritable confounding), which occurs when the genetic
195	instruments are associated with the exposure through their effect on confounders of an
196	exposure-outcome association[51, 52]. To mitigate this bias, we used Steiger filtering[53] to
197	remove SNPs that are more strongly associated with smoking behaviour (a confounder of
198	the exposure-outcome association) than the exposure of interest, as proposed by Sanderson
199	et al.[54]. We also used Causal Analysis using Summary Effect Estimates (CAUSE)[52],
200	another pleiotropy-robust MR method, to further investigate whether our results could be
201	biased by correlated horizontal pleiotropy. CAUSE uses Bayesian expected log pointwise
202	posterior predictive densities (ELPDs) to compare null, sharing and causal models. A higher
203	ELPD represents a better model fit, so a positive delta ELPD (where delta ELPD = ELPD model
204	1 - ELPD model 2) suggests model 1 fits the data better than model 2, while a negative delta
205	ELPD suggests the opposite. If we find evidence to reject the null hypothesis that the sharing
206	model (i.e. causal effect fixed at zero) fits the data at least as well as the causal model (i.e.
207	causal effect can differ from zero), our findings would be consistent with a causal effect.
208	Steiger filtering and CAUSE analyses were only conducted for adiposity measures with
209	evidence of a total effect in our main IVW analyses.

210

Moreover, we used the MR-Clust algorithm[55] to find distinct SNP clusters underlying the relationship between adiposity measures with evidence of a total effect in our main analyses and HNC. The identification of substantial clusters could provide insight into potential causal mechanisms. It could also flag pleiotropic variables that are associated with SNPs in each

It is made available under a CC-BY 4.0 International license .

215	cluster W	e filtered 9	SNPs with a	conditional	nrohabilities.	<08 At	least four	SNPs needed to
<b>ZI</b> J	CIUSIEI. VV	e intereu .		Jununuonai	probabilities	NU.0. AL	ieast iour .	JINFS HEEGEG LU

remain per cluster for a substantial cluster to be reported.

217

#### 218 Secondary analyses

- 219 In secondary analyses, we investigated the role of BMI, WHR and waist circumference on the
- 220 risk of HNC by subsite (i.e., oral cavity, hypopharynx, HPV positive oropharynx, HPV negative
- oropharynx and larynx). We used a Cochran's Q test to examine heterogeneity across HNC

222 subsites.

- 223
- 224 We also explored the role of other adiposity-related anthropometric measures on the risk of

225 HNC and its subsites. These anthropometric measures included: 1) four body shape principal

components[56], 2) childhood and adulthood body size[57], 3) metabolically favourable and

227 unfavourable adiposity[58], 4) body fat percentage, and 5) brain and adipose tissue-specific

BMI[59]. The data sources for these traits are summarised in **Table 1**.

230 Table 1. Data sources and instruments for other adiposity-related anthropometric i	measures
--	----------

Study	Year	Data source	Trait	Unit	Download link or OpenGWAS ID
Ried et al.[56]	2016	GIANT	Body shape PC1 (overall adiposity)	SD	https://www.joelhirsc hhornlab.org/giant-
			Body shape PC2 (tall and	SD	<u>consortium-results</u>
			slim vs short and plump)		_
			Body shape PC3 (tall	SD	
			with small hip vs short		
			with big hip)		
			Body shape PC4 (high	SD	
			BM∣ and weight with		
			small hip and waist vs		
			low BMI and weight		
			with big hip and waist)		
Richardson et al. [57]	2020	UKB	Childhood body size	Change in body	"ieu-b-5107"
				size category	
			Adulthood body size	Change in body	"ieu-b-5118"
				size category	
Martin et al.[58]	2021	υκв	Metabolically favourable	SD	https://doi.org/10.23
			adiposity		37/figshare.14555463

It is made available under a CC-BY 4.0 International license .

			Metabolically	SD	<u>.v1</u>
			unfavou rable adiposity		
MRC-IEU (Elsworth)	2018	UKB	Body fat percentage	SD	"u kb-b-8909"
Leyden et al. [59]	2022	GIANT + UKB	Brain tissue-specific BMI	SD	https://www.ncbi.nlm
			Adipose tissu e-specific	SD	.nih.gov/pmc/articles
			ВМІ		<u>/PMC8874216/bin/m</u>
					mc2 xlsx

231 232

Abbreviations: BMI, body mass index; GIANT, Genetic Investigation of Anthropometric Traits; N, number; PC, principal component; SD, standard deviation; SNP, single-nucleotide polymorphism; UKB, UK Biobank.

233 234

#### 235 Statistical software

- 236 We completed all MR analyses using R software version 4.4.0 and the "TwoSampleMR"
- 237 v0.6.3, "MRPRESSO" v1.0, "MVMR" v0.4, "cause" v1.2.0 and "mrclust" v0.1.0 R packages.
- The "ggplot2" v3.5.1 and "ggforestplot" v0.1.0 R packages were used to create forest plots.
- 239 The code used to run the MR analyses is available at
- 240 <u>http://github.com/fernandam93/adiposity\_HNC\_MR</u>.
- 241

## 242 **Results**

- 243 Genetic instruments for BMI, WHR and waist circumference
- 244 After data harmonisation and the removal of ambiguous palindromic SNPs, 442 genetic
- 245 variants remained as instruments for BMI, while 267 remained for WHR and 37 for waist
- circumference (Additional File 2: Supplementary Table 1). The mean F-statistic for BMI was
- 247 77 (range 33-844) and the total variance explained was 4.8%. For WHR, the mean F-statistic
- 248 was 73 (range 33–820) and the total variance explained was 3.1%. For waist circumference,
- the mean F-statistic was 50 (range 29–144) and the total variance explained was 0.8%.

- 251 The F-statistics and R<sup>2</sup> values for the other adiposity-related anthropometric measures have
- been summarised in **Table 2**.

It is made available under a CC-BY 4.0 International license .

#### 253

#### 254 Table 2. F-statistics and variance explained for other adiposity-related anthropometric

#### 255 measures.

Trait	N SNPs before/after harmonisation	Total R <sup>2</sup>	Mean F-statistics (range)
Body shape PC1 (overall adiposity)	29/28	16%	54 (28–302)
Body shape PC2 (tall and slim vs short and plump)	84/81	3.4%	54 (30–211)
Body shape PC3 (tall with small hip vs short with big hip)	28/27	0.9%	41 (30-82)
Body shape PC4 (high BMI and weight with small hip and waist vs low BMI and weight with big hip and waist)	10/10	24.7%	42 (30–98)
Childhood body size	206/198	3.4%	78 (28–1102)
Adulthood body size	339/324	4.2%	59 (30–1109)
Metabolically favourable adiposity	34/31	0.4%	64 (25–400)
Metabolically unfavourable adiposity	29/27	0.8%	131 (25–400)
Body fat percentage	377/360	4.7%	59 (30–682)
Brain tissue-specific BM	140/133	1.2%	61 (29–270)
Adipose tissue-specific BM	86 /81	0.7%	63 (30-270)

#### 256 257

\_\_\_\_

258

#### 259 Genetically predicted effects of BMI, WHR and waist circumference on HNC

260 risk

261 In univariable MR, higher genetically predicted BMI increased the risk of overall HNC (IVW

262 OR=1.17 per 1 standard deviation [1-SD] higher BMI, 95% CI 1.02–1.34, p=0.03), with no

heterogeneity across subsites (Q p=0.78) (Figure 1, Supplementary Figure 1 and Additional

264 File 2: Supplementary Table 7). However, the positive relationship between genetically

265 predicted BMI and HNC risk was not consistent across the MR-Egger, weighted median and

266 weighted mode analyses, with point estimates in opposing directions and confidence

267 intervals including the null. The Q statistic and MR-Egger intercept tests suggested that there

was heterogeneity across individual SNP estimates (Q=609, p<0.001) and a minor degree of

unbalanced horizontal pleiotropy (intercept=0.007, p=0.03) that could have biased the main

270 IVW results (Additional File 2: Supplementary Tables 8 and 9). Although the MR-PRESSO

analysis identified two outliers (i.e., rs11611246 and rs9603697), the distortion test

It is made available under a CC-BY 4.0 International license .

- suggested the outlier-corrected estimate (outlier-corrected IVW OR=1.14 per 1-SD higher
- 273 BMI, 95% CI 1.00–1.30, p=0.05) was not statistically different to the main IVW estimate
- 274 (p=0.94) (Additional File 2: Supplementary Table 10).
- 275
- 276 Furthermore, we did not find a link between genetically predicted WHR and HNC risk (IVW
- 277 OR=1.05 per 1-SD higher WHR, 95% CI 0.89–1.24, p=0.53) and there was no heterogeneity
- across subsites (Q p=0.15) (Figure 2, Supplementary Figure 2 and Additional File 2:
- 279 Supplementary Table 7). MR-Egger, weighted median and weighted mode results were
- 280 consistent with a null effect. The Q statistic and MR-Egger intercept tests suggested that
- there was some evidence of SNP heterogeneity (Q=332, p=0.004) and unbalanced horizontal
- 282 pleiotropy (intercept=0.008, p=0.03) (Additional File 2: Supplementary Tables 8 and 9). The
- 283 MR-PRESSO analysis did not identify any significant outliers (Additional File 2:
- 284 Supplementary Table 10).
- 285
- 286 Similarly, we did not find a genetically predicted effect of waist circumference on HNC risk

287 (IVW OR=0.83 per 1-SD higher waist circumference, 95% CI 0.56–1.23, p=0.35) or evidence

of heterogeneity across subsites (Q p=0.60) (Figure 3, Supplementary Figure 3 and

289 Additional File 2: Supplementary Table 7). The MR-Egger, weighted median and weighted

- 290 mode consistently suggested the absence of an effect of waist circumference on HNC risk.
- 291 The Q statistic and MR-Egger intercept tests suggested SNP heterogeneity (Q=89, p<0.001)
- but no unbalanced horizontal pleiotropy (intercept=-0.019, p=0.30) (Additional File 2:

293 Supplementary Tables 8 and 9). The MR-PRESSO analysis identified three outliers (i.e.,

- rs3127553, rs6440003 and rs806794) but the distortion test suggested the outlier-corrected
- estimate (outlier-corrected IVW OR=0.77 per 1-SD higher waist circumference, 95% CI 0.59-

It is made available under a CC-BY 4.0 International license .

1.01, p=0.07) was not statistically different to the main IVW estimate (p=0.73) (Additional

- 297 File 2: Supplementary Table 10).
- 298
- 299 MVMR estimates for BMI on HNC risk after accounting for smoking behaviour
- 300 The effect of BMI on HNC risk was attenuated when smoking behaviour was included in the
- 301 MVMR model (OR accounting for CSI=0.93 per 1-SD higher BMI, 95% CI 0.78–1.12, p=0.47;
- 302 OR accounting for smoking initiation=1.09 per 1-SD higher BMI, 95% CI 0.88–1.34, p=0.43)
- 303 (Figures 4 and 5 and Additional File 2: Supplementary Table 11). Genetically predicted
- 304 smoking behaviour increased the risk of HNC even after accounting for BMI (CSI OR
- accounting for BMI=4.25 per 1-SD higher CSI, 95% CI 3.18–5.67, p<0.001; SI OR accounting
- for BMI=2.10 per 1-SD higher SI, 95% CI 1.61–2.73, p<0.001). The conditional F-statistics for
- 307 the BMI estimates were 30.5 and 30.3 in the CSI and smoking initiation analyses,
- 308 respectively (Additional File 2: Supplementary Table 11). They were slightly lower for the
- smoking behaviour estimates conditioning on BMI (13.4 and 19.5 in the CSI and smoking
- 310 initiation analyses, respectively).
- 311
- 312 MR estimate for BMI on HNC risk after Steiger filtering SNPs more strongly
- 313 associated with smoking behaviour than BMI
- 314 After removing six SNPs (i.e., rs10002111, rs2503185, rs264941, rs10858334, rs225882,
- rs2273175) that were more strongly associated with smoking behaviour (i.e., CSI or smoking
- initiation) than BMI, the genetically predicted effect of BMI on HNC risk slightly attenuated
- towards the null (Steiger filtered IVW OR=1.14 per 1-SD higher BMI, 95% CI 1.00–1.31,
- 318 p=0.05) (Additional File 2: Supplementary Table 12).
- 319

It is made available under a CC-BY 4.0 International license .

#### 320 CAUSE estimate for BMI on HNC risk

- 321 We did not find evidence against bias due to correlated pleiotropy, since the causal model
- did not fit the data much better than the sharing model (CAUSE OR 1.12 per 1-SD higher BMI,
- 323 95% credible interval 0.93–1.34, delta ELPD for sharing vs causal=-0.07, p=0.47)
- 324 (Supplementary Figure 4). Interestingly, neither the sharing nor the causal model fitted the
- data much better than the null model (delta ELPD for null vs sharing=-0.39, p=0.36; and
- delta ELPD for null vs causal=-0.46, p=0.41).
- 327

#### 328 MR-Clust estimates for the relationship between BMI and HNC risk

- 329 After filtering SNPs with conditional probabilities <0.8 and clusters with fewer than four
- SNPs (e.g., cluster 1, as only three of 17 SNPs remained after probability filtering), only a null
- 331 cluster including 372 SNPs (424 before filtering) remained in the MR-Clust output for BMI
- and HNC risk (Supplementary Figure 5 and Additional File 2: Supplementary Table 13).
- Hence, the MR-Clust analysis did not reveal any mechanistic pathways underlying the effect
- 334 observed.
- 335
- 336 Genetically predicted effects of other adiposity-related anthropometric
- 337 measures on HNC risk
- 338 We did not find consistent evidence of genetically predicted effects of other anthropometric
- 339 measures on HNC risk (Supplementary Figures 6–10 and Additional File 2: Supplementary
- **Table 14**). The IVW estimate for PC2 capturing a combination of taller height and slimmer
- 341 waist suggested this body shape decreased HNC risk (OR=0.86, 95% CI 0.75–0.99, p=0.04)
- 342 (Supplementary Figure 6b). Similarly, the IVW estimate for PC3 capturing a combination of
- taller height and narrower hips suggested this body shape also reduced HNC risk (OR=0.73,

It is made available under a CC-BY 4.0 International license .

344 95% CI 0.55–0.97, p=0.03) (**Supplementary Figure 6c**). However, these inverse relationships

345 were not consistent with results obtained using pleiotropy-robust methods (i.e., MR-Egger,

346 weighted median and weighted mode).

347

## 348 Discussion

349 In this MR study, we reaffirmed that there is no clear evidence of a genetically predicted 350 effect of adiposity (i.e., BMI, WHR and waist circumference) or related anthropometric 351 measures on the risk of HNC or its subsites. Although we found higher genetically predicted 352 BMI increased the risk of overall HNC in the main univariable MR analysis, this was not 353 consistent across the sensitivity analyses. Notably, the MVMR results suggested the main 354 analysis may have been biased by smoking (and/or related traits), as the effect disappeared 355 after accounting for smoking behaviour. The results obtained after Steiger filtering SNPs 356 more strongly associated with smoking behaviour than BMI suggested correlated pleiotropy 357 may have been partly biasing the BMI-HNC estimate. CAUSE, which is more robust to 358 correlated pleiotropy than the IVW method, further supported this hypothesis. 359 Our results are consistent with previous MR studies that suggest adiposity does not 360 361 influence HNC risk[27-29]. Gormley et al. [28] did not find a genetically predicted effect of 362 adiposity on combined oral and oropharyngeal cancer when investigating either BMI 363 (OR=0.89 per 1-SD, 95% CI 0.72–1.09, p=0.26), WHR (OR=0.98 per 1-SD, 95% CI 0.74–1.29, 364 p=0.88) or waist circumference (OR=0.73 per 1-SD, 95% CI 0.52–1.02, p=0.07) as risk factors. 365 Similarly, a large two-sample MR study by Vithayathil et al. [29] including 367,561 UK

Biobank participants (of which 1,983 were HNC cases) found no link between BMI and HNC

risk (OR=0.98 per 1-SD higher BMI, 95% CI 0.93–1.02, p=0.35). Larsson et al.[27] metaanalysed Vithayathil et al.'s[29] findings with results obtained using FinnGen data to increase
the sample size even further (N=586,353, including 2,109 cases), but still did not find a
genetically predicted effect of BMI on HNC risk (OR=0.96 per 1-SD higher BMI, 95% CI 0.77–
1.19, p=0.69).

372

373 In our study, we found some evidence that the genetically predicted effect of BMI on HNC 374 risk was influenced by smoking. This could be due to the bidirectional relationship between 375 smoking and adiposity reported in previous MR studies [17-22] or due to their shared genetic 376 architecture [60, 61]. A strength of our study was that it was the first to exploit MVMR to 377 disentangle the effects of BMI and smoking behaviour on the risk of HNC and its subsites. An 378 advantage of our approach compared to conducting univariable MR analyses stratified by 379 smoking status is that the former does not induce collider bias and provides estimates of 380 direct effects irrespective of horizontal pleiotropy or mediation. Yet, we acknowledge the 381 smoking behaviour traits used in our MVMR analyses likely capture more than just smoking, 382 since some of the SNPs used to instrument these traits have been associated with risk-taking 383 phenotypes and socioeconomic factors[62-65]. This places limits in the inferences that can 384 be made about smoking in the context of mediation.

385

An important strength of our study was that the HEADSpAcE consortium GWAS used had a large sample size which conferred more statistical power to detect effects of adiposity on HNC risk compared to previous MR analyses[27-29], increasing one's confidence in the null nature of the estimates. Furthermore, the availability of data on more HNC subsites, including oropharyngeal cancers by HPV status, allowed us to investigate the relationship

391	between adiposity and HNC risk in more detail than previous MR studies which limited their
392	subsite analyses to oral cavity and overall oropharyngeal cancers[28, 66]. This is relevant
393	because distinct HNC subsites are known to have different aetiologies[67], although we did
394	not find evidence of heterogeneity across subsites in our study.
395	
396	We acknowledge that a major limitation of MR studies, including ours, is that several
397	untestable assumptions are required to make accurate causal inferences. It is unlikely that
398	our findings were influenced by weak instrument bias (i.e., violating the relevance
399	assumption) because we used strong genetic instruments to proxy our adiposity traits.
400	However, the independence assumption of no genetic confounding and the exclusion
401	restriction assumption of no horizontal pleiotropy could have been violated.
402	
403	While our study contributes valuable evidence on the role of adiposity in the development
404	of HNC, we recognise there is a need for additional research on the subject. Our study was
405	limited to individuals of European ancestry, so our findings should be replicated in other
406	ancestry groups before being generalised to non-European populations. Moreover, further
407	research is needed to understand the biology underlying the complex relationship between
408	smoking and adiposity, especially since it may be difficult to intervene on one without
409	influencing the other[17].
410	

# 411 Conclusions

412 In conclusion, this study indicates that adiposity does not play a role in HNC risk. Although
413 we did not find strong evidence of a causal effect of adiposity on HNC, obesity is an

It is made available under a CC-BY 4.0 International license .

- 414 established risk factor for multiple cancers and other chronic diseases[27, 68, 69]. Hence
- 415 there is still value in aiming to reduce the levels of excess adiposity in the population.

416

# 417 **References**

418	1.	Global Cancer Observatory: Cancer Today (version 1.1)
419		[https://gco.iarc.who.int/today]
420	2.	Curado MP, Hashibe M: Recent changes in the epidemiology of head and neck
421		<b>cancer</b> . <i>Curr Opin Oncol</i> 2009, <b>21</b> (3):194-200.
422	3.	Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L,
423		Daudt AW, Fabianova E, Fernandez L et al: Alcohol drinking in never users of tobacco,
424		cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled
425		analysis in the International Head and Neck Cancer Epidemiology Consortium. J
426		Natl Cancer Inst 2007, <b>99</b> (10):777-789.
427	4.	Lee YC, Boffetta P, Sturgis EM, Wei Q, Zhang ZF, Muscat J, Lazarus P, Matos E, Hayes
428		RB, Winn DM et al: Involuntary smoking and head and neck cancer risk: pooled
429		analysis in the International Head and Neck Cancer Epidemiology Consortium.
430		Cancer Epidemiol Biomarkers Prev 2008, <b>17</b> (8):1974-1981.
431	5.	Purdue MP, Hashibe M, Berthiller J, La Vecchia C, Dal Maso L, Herrero R, Franceschi S,
432		Castellsague X, Wei Q, Sturgis EM <i>et al</i> : <b>Type of alcoholic beverage and risk of head</b>
433		and neck cancera pooled analysis within the INHANCE Consortium. Am J
434		Epidemiol 2009, <b>169</b> (2):132-142.
435	6.	Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal
436		Maso L, Daudt AW, Fabianova E <i>et al</i> : I <b>nteraction between tobacco and alcohol use</b>
437		and the risk of head and neck cancer: pooled analysis in the International Head and
438		Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009,
439		<b>18</b> (2):541-550.
440	7.	Marron M, Boffetta P, Zhang ZF, Zaridze D, Wunsch-Filho V, Winn DM, Wei Q,
441		Talamini R, Szeszenia-Dabrowska N, Sturgis EM <i>et al</i> : <b>Cessation of alcohol drinking,</b>
442		tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2010,
443		<b>39</b> (1):182-196.
444	8.	Humans IWGotEoCRt: Tobacco smoke and involuntary smoking. IARC Monogr Eval
445		Carcinog Risks Hum 2004, <b>83</b> :1-1438.
446	9.	Gormley M, Dudding T, Sanderson E, Martin RM, Thomas S, Tyrrell J, Ness AR,
447		Brennan P, Munafo M, Pring M et al: A multivariable Mendelian randomization
448		analysis investigating smoking and alcohol consumption in oral and oropharyngeal
449		<b>cancer</b> . Nat Commun 2020, <b>11</b> (1):6071.
450	10.	Sabatini ME, Chiocca S: Human papillomavirus as a driver of head and neck cancers.
451		Br J Cancer 2020, <b>122</b> (3):306-314.
452	11.	Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML,
453		Daniel RW, Viglione M, Symer DE <i>et al</i> : <b>Evidence for a causal association between</b>
454		human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst
455		2000, <b>92</b> (9):709-720.

456	12.	de Martel C, Georges D, Bray F, Ferlay J, Clifford GM: <b>Global burden of cancer</b>
457		attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob
458		<i>Health</i> 2020, <b>8</b> (2):e180-e190.
459	13.	Research WCRFAIfC: Diet, nutrition, physical activity and cancers of the mouth,
460		pharynx and larynx. In: Continuous Update Project Expert Report. 2018.
461	14.	Gaudet MM, Kitahara CM, Newton CC, Bernstein L, Reynolds P, Weiderpass E,
462		Kreimer AR, Yang G, Adami HO, Alavanja MC <i>et al</i> : Anthropometry and head and
463		neck cancer:a pooled analysis of cohort data. Int J Epidemiol 2015, 44(2):673-681.
464	15.	Jo YH, Talmage DA, Role LW: Nicotinic receptor-mediated effects on appetite and
465		food intake. J Neurobiol 2002, 53(4):618-632.
466	16.	Watts EL, Moore SC, Gunter MJ, Chatterjee N: Adiposity and cancer: meta-analysis,
467		mechanisms, and future perspectives. medRxiv
468		2024: <u>https://doi.org/10.1101/2024.1102.1116.24302944</u> .
469	17.	Taylor AE, Richmond RC, Palviainen T, Loukola A, Wootton RE, Kaprio J, Relton CL,
470		Davey Smith G, Munafo MR: The effect of body mass index on smoking behaviour
471		and nicotine metabolism: a Mendelian randomization study. Hum Mol Genet 2019,
472		<b>28</b> (8):1322-1330.
473	18.	Carreras-Torres R, Johansson M, Haycock PC, Relton CL, Davey Smith G, Brennan P,
474		Martin RM: Role of obesity in smoking behaviour: Mendelian randomisation study
475		in UK Biobank. <i>BMJ</i> 2018, <b>361</b> :k1767.
476	19.	Asvold BO, Bjorngaard JH, Carslake D, Gabrielsen ME, Skorpen F, Smith GD,
477		Romundstad PR: Causal associations of tobacco smoking with cardiovascular risk
478		factors: a Mendelian randomization analysis of the HUNT Study in Norway. Int J
479		Epidemiol 2014, <b>43</b> (5):1458-1470.
480	20.	Freathy RM, Kazeem GR, Morris RW, Johnson PC, Paternoster L, Ebrahim S, Hattersley
481		AT, Hill A, Hingorani AD, Holst C et al: Genetic variation at CHRNA5-CHRNA3-CHRNB4
482		interacts with smoking status to influence body mass index. Int J Epidemiol 2011,
483		<b>40</b> (6):1617-1628.
484	21.	Taylor AE, Morris RW, Fluharty ME, Bjorngaard JH, Asvold BO, Gabrielsen ME,
485		Campbell A, Marioni R, Kumari M, Hallfors J et al: Stratification by smoking status
486		reveals an association of CHRNA5-A3-B4 genotype with body mass index in never
487		smokers. PLoS Genet 2014, 10(12):e1004799.
488	22.	Morris RW, Taylor AE, Fluharty ME, Bjorngaard JH, Asvold BO, Elvestad Gabrielsen M,
489		Campbell A, Marioni R, Kumari M, Korhonen T <i>et al</i> : <b>Heavier smoking may lead to a</b>
490		relative increase in waist circumference: evidence for a causal relationship from a
491		Mendelian randomisation meta-analysis. The CARTA consortium. BMJ Open 2015,
492		<b>5</b> (8):e008808.
493	23.	Yang S, Lynch J, Schulenberg J, Diez Roux AV, Raghunathan T: <b>Emergence of</b>
494		socioeconomic inequalities in smoking and overweight and obesity in early
495		adulthood: the national longitudinal study of adolescent health. Am J Public Health
496		2008, <b>98</b> (3):468-477.
497	24.	Marmot M, Bell R: Social determinants and non-communicable diseases: time for
498		integrated action. BMJ 2019, 364:1251.
499	25.	Marmot M: The health gap: Doctors and the social determinants of health. Scand J
500		Public Health 2017, <b>45</b> (7):686-693.
501	26.	Filippidis FT, Agaku IT, Girvalaki C, Jimenez-Ruiz C, Ward B, Gratziou C, Vardavas CI,
502		Tobacco Control Committee of the European Respiratory S: Relationship of

503		secondhand smoke exposure with sociodemographic factors and smoke-free
504		legislation in the European Union. <i>Eur J Public Health</i> 2016, <b>26</b> (2):344-349.
505	27.	Larsson SC, Burgess S: Causal role of high body mass index in multiple chronic
506		diseases: a systematic review and meta-analysis of Mendelian randomization
507		studies. BMC Med 2021, 19(1):320.
508	28.	Gormley M, Dudding T, Thomas SJ, Tyrrell J, Ness AR, Pring M, Legge D, Davey Smith
509		G, Richmond RC, Vincent EE et al: Evaluating the effect of metabolic traits on oral
510		and oropharyngeal cancer risk using Mendelian randomization. Elife 2023, 12.
511	29.	Vithayathil M, Carter P, Kar S, Mason AM, Burgess S, Larsson SC: Body size and
512		composition and risk of site-specific cancers in the UK Biobank and large
513		international consortia: A mendelian randomisation study. PLoS Med 2021,
514		<b>18</b> (7):e1003706.
515	30.	Lesseur C, Diergaarde B, Olshan AF, Wunsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-
516		Neto J, Franceschi S, Lagiou P et al: Genome-wide association analyses identify new
517		susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet 2016,
518		<b>48</b> (12):1544-1550.
519	31.	Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation studies:
520		a guide, glossary, and checklist for clinicians. BMJ 2018, 362:k601.
521	32.	Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA,
522		VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N <i>et al</i> : <b>Strengthening the</b>
523		Reporting of Observational Studies in Epidemiology Using Mendelian
524		Randomization: The STROBE-MR Statement. JAMA 2021, 326(16):1614-1621.
525	33.	Ebrahimi E, Sangphukieo A, Park H, Gaborieau V, Ferreiro-Iglesias A, Diergaarde B,
526		Ahrens W, Alemany L, Arantes L, Betka J et al: Cross-ancestral GWAS identifies 29
527		novel variants across Head and Neck Cancer subsites. medRxiv
528		2024: <u>https://doi.org/10.1101/2024.1111.1118.24317473</u> .
529	34.	World Health O, World Health O: ICD-10 : international statistical classification of
530		diseases and related health problems, Tenth revision, Fifth edition. edn. Geneva:
531		World Health Organization; 2016.
532	35.	Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, Strawbridge
533		RJ, Pers TH, Fischer K, Justice AE et al: New genetic loci link adipose and insulin
534		biology to body fat distribution. Nature 2015, 518(7538):187-196.
535	36.	Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, Yengo L, Ferreira
536		T, Marouli E, Ji Y et al: Meta-analysis of genome-wide association studies for body
537		fat distribution in 694 649 individuals of European ancestry. Hum Mol Genet 2019,
538		<b>28</b> (1):166-174.
539	37.	Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem RM,
540		Chasman DI, Ridker PM, Neale BM, Berger B et al: Efficient Bayesian mixed-model
541		analysis increases association power in large cohorts. Nat Genet 2015, 47(3):284-
542		290.
543	38.	Willer CJ, Li Y, Abecasis GR: METAL: fast and efficient meta-analysis of genomewide
544		association scans. Bioinformatics 2010, 26(17):2190-2191.
545	39.	Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S,
546		Bowden J, Langdon R et al: The MR-Base platform supports systematic causal
547		inference across the human phenome. Elife 2018, 7.

It is made available under a CC-BY 4.0 International license .

548	40.	Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ, Davey
549		Smith G, Sterne JA: Using multiple genetic variants as instrumental variables for
550		modifiable risk factors. Stat Methods Med Res 2012, 21(3):223-242.
551	41.	Burgess S, Thompson SG: Bias in causal estimates from Mendelian randomization
552		studies with weak instruments. Stat Med 2011, 30(11):1312-1323.
553	42.	Burgess S, Butterworth A, Thompson SG: Mendelian randomization analysis with
554		multiple genetic variants using summarized data. Genet Epidemiol 2013, 37(7):658-
555		665.
556	43.	Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid
557		instruments: effect estimation and bias detection through Egger regression. Int J
558		Epidemiol 2015, <b>44</b> (2):512-525.
559	44.	Bowden J, Davey Smith G, Haycock PC, Burgess S: <b>Consistent Estimation in</b>
560		Mendelian Randomization with Some Invalid Instruments Using a Weighted
561		Median Estimator. Genet Epidemiol 2016. 40(4):304-314.
562	45.	Hartwig FP. Davey Smith G. Bowden J: Robust inference in summary data Mendelian
563		randomization via the zero modal pleiotropy assumption. Int J Epidemiol 2017.
564		<b>46</b> (6):1985-1998.
565	46.	Bowden J. Del Greco MF. Minelli C. Zhao O. Lawlor DA. Sheehan NA. Thompson J.
566		Davey Smith G: Improving the accuracy of two-sample summary-data Mendelian
567		randomization: moving beyond the NOME assumption. Int J Enidemiol 2019.
568		<b>48</b> (3):728-742.
569	47.	Verbanck M. Chen CY. Neale B. Do R: <b>Detection of widespread horizontal pleiotropy</b>
570		in causal relationships inferred from Mendelian randomization between complex
571		traits and diseases. Nat Genet 2018, 50(5):693-698.
572	48.	Sanderson E, Davey Smith G, Windmeijer F, Bowden J: An examination of
573		multivariable Mendelian randomization in the single-sample and two-sample
574		summary data settings. Int J Epidemiol 2019, <b>48</b> (3):713-727.
575	49.	Saunders GRB, Wang X, Chen F, Jang S-K, Liu M, Wang C, Gao S, Jiang Y,
576		Khunsriraksakul C, Otto JM et al: Genetic diversity fuels gene discovery for tobacco
577		and alcohol use. Nature 2022, 612(7941):720-724.
578	50.	Wootton RE, Richmond RC, Stuijfzand BG, Lawn RB, Sallis HM, Taylor GMJ, Hemani G,
579		Jones HJ, Zammit S, Davey Smith G <i>et al:</i> Evidence for causal effects of lifetime
580		smoking on risk for depression and schizophrenia: a Mendelian randomisation
581		<b>study</b> . <i>Psychol Med</i> 2020, <b>50</b> (14):2435-2443.
582	51.	Darrous L, Mounier N, Kutalik Z: Simultaneous estimation of bi-directional causal
583		effects and heritable confounding from GWAS summary statistics. Nat Commun
584		2021, <b>12</b> (1):7274.
585	52.	Morrison J, Knoblauch N, Marcus JH, Stephens M, He X: Mendelian randomization
586		accounting for correlated and uncorrelated pleiotropic effects using genome-wide
587		summary statistics. Nat Genet 2020, 52(7):740-747.
588	53.	Hemani G, Tilling K, Davey Smith G: <b>Orienting the causal relationship between</b>
589		imprecisely measured traits using GWAS summary data. PLoS Genet 2017,
590		<b>13</b> (11):e1007081.
591	54.	Sanderson E, Rosoff D, Palmer T, Tilling K, Smith GD, Hemani G: Bias from heritable
592		confounding in Mendelian randomization studies. medRxiv
593		2024:2024.2009.2005.24312293.

594	55.	Foley CN, Mason AM, Kirk PDW, Burgess S: MR-Clust: clustering of genetic variants
595		in Mendelian randomization with similar causal estimates. Bioinformatics 2021,
596		<b>37</b> (4):531-541.
597	56.	Ried JS, Jeff MJ, Chu AY, Bragg-Gresham JL, van Dongen J, Huffman JE, Ahluwalia TS,
598		Cadby G, Eklund N, Eriksson J et al: A principal component meta-analysis on
599		multiple anthropometric traits identifies novel loci for body shape. Nat Commun
600		2016, 7:13357.
601	57.	Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G: Use of genetic
602		variation to separate the effects of early and later life adiposity on disease risk:
603		mendelian randomisation study. BMJ 2020, 369:m1203.
604	58.	Martin S, Cule M, Basty N, Tyrrell J, Beaumont RN, Wood AR, Frayling TM, Sorokin E,
605		Whitcher B, Liu Y et al: Genetic Evidence for Different Adiposity Phenotypes and
606		Their Opposing Influences on Ectopic Fat and Risk of Cardiometabolic Disease.
607		Diabetes 2021, <b>70</b> (8):1843-1856.
608	59.	Leyden GM, Shapland CY, Davey Smith G, Sanderson E, Greenwood MP, Murphy D,
609		Richardson TG: Harnessing tissue-specific genetic variation to dissect putative
610		causal pathways between body mass index and cardiometabolic phenotypes. Am J
611		Hum Genet 2022, <b>109</b> (2):240-252.
612	60.	Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U,
613		Thorleifsson G, Walters GB, Consortium TAG, Oxford GSKC, consortium E <i>et al</i> : <b>A</b>
614		common biological basis of obesity and nicotine addiction. <i>Transl Psychiatry</i> 2013,
615		<b>3</b> (10):e308.
616	61.	Wills AG, Hopfer C: Phenotypic and genetic relationship between BMI and cigarette
617		smoking in a sample of UK adults. Addict Behav 2019, 89:98-103.
618	62.	Gage SH, Sallis HM, Lassi G, Wootton RE, Mokrysz C, Davey Smith G, Munafo MR:
619		Does smoking cause lower educational attainment and general cognitive ability?
620		Triangulation of causal evidence using multiple study designs. Psychol Med 2022,
621		<b>52</b> (8):1578-1586.
622	63.	Schellhas L, Haan E, Easey KE, Wootton RE, Sallis HM, Sharp GC, Munafo MR, Zuccolo
623		L: Maternal and child genetic liability for smoking and caffeine consumption and
624		child mental health: an intergenerational genetic risk score analysis in the ALSPAC
625		cohort. Addiction 2021, 116(11):3153-3166.
626	64.	Khouja JN, Wootton RE, Taylor AE, Davey Smith G, Munafo MR: Association of
627		genetic liability to smoking initiation with e-cigarette use in young adults: A cohort
628		study. PLoS Med 2021, 18(3):e1003555.
629	65.	Reed ZE, Wootton RE, Khouja JN, Richardson TG, Sanderson E, Davey Smith G,
630		Munafo MR: Exploring pleiotropy in Mendelian randomisation analyses: What are
631		genetic variants associated with 'cigarette smoking initiation' really capturing?
632		Genet Epidemiol 2024.
633	66.	Gui L, He X, Tang L, Yao J, Pi J: Obesity and head and neck cancer risk: a mendelian
634		randomization study. BMC Med Genomics 2023, 16(1):200.
635	67.	Thomas SJ, Penfold CM, Waylen A, Ness AR: The changing aetiology of head and
636		neck squamous cell cancer: A tale of three cancers? Clin Otolaryngol 2018,
637		<b>43</b> (4):999-1003.
638	68.	Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, International
639		Agency for Research on Cancer Handbook Working G: Body Fatness and Cancer
640		Viewpoint of the IARC Working Group. N Engl J Med 2016, 375(8):794-798.

It is made available under a CC-BY 4.0 International license .

641 69. Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P: Commentary:
642 What can Mendelian randomization tell us about causes of cancer? Int J Epidemiol
643 2019, 48(3):816-821.

644

645

# 646 Availability of data and materials

- 647 All the GWAS datasets used in our study are publicly available. The GWAS summary statistics
- 648 for waist circumference by Shungin et al. are available via the IEU OpenGWAS platform (id:
- 649 ieu-a-61). The GWAS summary statistics for BMI and WHR by Pulit et al.[36] can be
- 650 downloaded from <u>https://zenodo.org/records/1251813</u>. The data sources for the other
- adiposity-related measures have been specified in Table 1. The smoking behaviour traits
- 652 GWAS data were downloaded from
- 653 <u>https://data.bris.ac.uk/data/dataset/10i96zb8gm0j81yz0q6ztei23d</u> (for CSI) and
- 654 <u>https://doi.org/10.13020/przg-dp88</u> (for smoking initiation). The outcome datasets used in
- our analyses have been uploaded to the IEU OpenGWAS project platform for reproducibility.
- 656 However, because the data was originally in build GRCh38, some multiallelic SNPs that could
- not be aligned with GRCh37 Human Genome reference sequence were dropped when lifting
- the data to build HG19/GRCh37 (which was required at the time of upload: April 2024). The
- 659 following IEU OpenGWAS id's were assigned to the European HEADSpAcE HNC GWAS
- 660 datasets including/excluding UK Biobank: ieu-b-5129/ieu-b-5123 for overall HNC, ieu-b-
- 661 5132/ieu-b-5126 for oral cavity cancer, ieu-b-5130/ieu-b-5124 for hypopharynx cancer, ieu-
- 662 b-5134/ieu-b-5128 for HPV positive oropharynx cancer, ieu-b-5133/ieu-b-5127 for HPV
- 663 negative oropharynx cancer, and ieu-b-5131/ieu-b-5125 for larynx cancer. The R code used
- to run the MR analyses is available at <u>http://github.com/fernandam93/adiposity\_HNC\_MR</u>.

It is made available under a CC-BY 4.0 International license .

## 666 Acknowledgements

- 667 We thank Richard Wilkinson for proofreading several versions of the manuscript. We would
- also like to thank Weili (Jason) Qiu, the IEU Data Manager, for his help debugging code and
- uploading the HNC GWAS summary statistics to the IEU OpenGWAS platform.
- 670

# 671 Funding

- 672 FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and
- 673 Lifecourse Epidemiology (224982/Z/22/Z). RCR was supported by a Cancer Research UK
- 674 grant (C18281/A29019). MCB is supported by a University of Bristol Vice Chancellor's
- Fellowship, the British Heart Foundation (AA/18/1/34219) and the UK Medical Research
- 676 Council (MC\_UU\_00032/05). GDS works within the MRC Integrative Epidemiology Unit at
- the University of Bristol, which is supported by the Medical Research Council
- 678 (MC\_UU\_00011/1). CLR was supported by the Medical Research Council (MC\_UU\_00011/5)
- and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer
- 680 Epidemiology Programme). SV was funded by an EU Horizon 2020 grant (agreement number
- 681 825771). JK works in a unit that receives support from the University of Bristol and the UK
- 682 Medical Research Council (grant number: MC\_UU\_00032/7).
- 683

# 684 Competing interests

585 TGR works as a full-time employee for GlaxoSmithKline outside of this research. All other

686 authors declare no conflicts of interest.

It is made available under a CC-BY 4.0 International license .

## 688 IARC disclaimer

- 689 Where authors are identified as personnel of the International Agency for Research on
- 690 Cancer/World Health Organization, the authors alone are responsible for the views
- 691 expressed in this article and they do not necessarily represent the decisions, policy or views
- 692 of the International Agency for Research on Cancer/World Health Organization

# **Figures**



Figure 1. Forest plot for the genetically predicted effects of body mass index on the risk of head and neck cancer and its subsites.

It is made available under a CC-BY 4.0 International license .



Figure 2. Forest plot for the genetically predicted effects of waist-to-hip ratio on the risk of head and neck cancer and its subsites.



*Figure 3. Forest plot for the genetically predicted effects of waist circumference on the risk of head and neck cancer and its subsites.* 

It is made available under a CC-BY 4.0 International license .



Figure 4. Forest plot for the genetically predicted effects of BMI on the risk of HNC and its subsites, before (univariable-black) and after (multivariable-blue) accounting for comprehensive smoking index (CSI).



Figure 5. Forest plot for the genetically predicted effects of BMI on the risk of HNC and its subsites, before (univariable-black) and after (multivariable-blue) accounting for smoking initiation (SI).